Systematic Review or Meta Analysis

Candidalysin is a toxin from Candida albicans that can damage epithelial barriers and trigger inflammation. If candidalysin contributes to intestinal inflammation or barrier dysfunction, it could help explain fungal...

People with UC often use probiotics or microbiome-directed therapies alongside prescription drugs. Understanding probiotic–drug interactions could explain why individuals respond differently to IBD treatments and may...

Transmural healing may better reflect the full depth of inflammation in Crohn’s disease than mucosal healing alone and is associated with improved long-term outcomes in many studies. If validated and adopted, TH could...

Extraintestinal manifestations (skin, joint, eye, liver) are common in IBD and can greatly affect quality of life; better recognition and coordinated care can speed diagnosis and improve outcomes.

GPX and selenium-related pathways may be important to how oxidative stress, ferroptosis, and the microbiome contribute to IBD. Understanding these mechanisms could guide future therapies.

This paper outlines research strategies aiming to deliver drugs more precisely to inflamed gut tissue and to reshape immune-cell behavior — advances that could eventually lead to safer, more targeted IBD treatments. It’s...

Macrophages are central regulators of intestinal inflammation and repair; understanding their diversity and how to modulate them could lead to new, more targeted treatments for Crohn's disease and ulcerative colitis.

Endoscopic scores guide detection and treatment of postoperative Crohn's recurrence; better scoring could change who gets earlier therapy and potentially prevent clinical or surgical relapse.

A pooled analysis of cardiovascular risk tied to advanced IBD therapies could affect treatment decisions and monitoring plans because some immune-targeted drugs have been linked to cardiovascular safety concerns in other...

Defining whether IBD therapies prevent long-term damage matters to patients and clinicians because it affects treatment goals and long-term care planning.

Better detection of enteric infections during suspected IBD flares could help avoid unnecessary escalation of immunosuppressive therapy and guide appropriate antibiotic use. This review suggests MPCR finds more pathogens...

Targeting IL‑1 is a promising route to reduce gut inflammation in IBD, but existing IL‑1 drugs face delivery and stability challenges. Nanocarriers could improve how these agents reach inflamed intestinal tissue, which...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease and Research and clinical trials. The original article is from Saudi journal of...

The review directly compares randomized-trial evidence for JAK inhibitors in moderate-to-severe Crohn's disease and highlights which regimens (notably upadacitinib) showed the most consistent efficacy signals,...

People with suspected or known IBD and their clinicians want accurate, noninvasive tests to detect inflammation. This review suggests NGAL may be sensitive for identifying IBD but existing data are limited and uncertain,...

Ulcerative colitis changes the colonic environment in ways that can make current mesalazine formulations release unpredictably. New delivery approaches aimed at stabilising drug interfaces could lead to more consistent...

This analysis directly addresses treatments commonly used for perianal fistulizing Crohn’s disease and compares biologic anti-TNF drugs with emerging mesenchymal stem cell therapy, information that could affect treatment...

The ENS–gut microbiota field intersects with IBD research through shared mechanisms (neuroinflammation, neuro‑immune interactions) and potential microbiota‑based therapies, so mapping trends helps patients and clinicians...

Microplastics are a widespread environmental exposure that this review links to biological changes relevant to IBD — intestinal barrier damage, microbiome shifts, and immune activation — so patients and clinicians may...

IL-22 links microbial metabolites to epithelial repair and inflammation; clarifying these pathways could inform future therapies or dietary/microbiome approaches to promote mucosal healing without worsening inflammation.

Patients with hidradenitis suppurativa have higher baseline IBD risk, and IL-17 inhibitors are effective HS treatments. People with Crohn’s disease or ulcerative colitis (or those at risk) may worry whether these drugs...

Depression is common in Crohn’s disease and appears linked to immune and microbial signals from the gut. Understanding gut–brain mechanisms could improve how mood symptoms are detected and treated in people with IBD.

AMPs are central to gut immune balance and are being explored as new therapies for IBD and related gut diseases. For people with Crohn’s or IBD, understanding AMPs helps explain research directions aimed at restoring...

This review highlights shared biomarkers and mechanisms between early Crohn's disease and post-operative recurrence, which could improve prediction and lead to preventive strategies for recurrence after surgery.

Dysplasia detection during colonoscopy is central to preventing colorectal cancer in people with IBD. AI tools could help, but current models often fail in inflamed or IBD-specific settings, so this review outlines...

People with IBD commonly experience anxiety, depression, and other neurological symptoms. Understanding gut–brain axis mechanisms may help explain these comorbidities and point to future treatments.

Many people with IBD also have overweight or obesity; GLP-1 receptor agonists are being used for weight loss and may affect inflammation and IBD outcomes. This review summarizes current evidence on safety, effectiveness,...

The microbiome is connected to IBD through effects on immune regulation and barrier function; advances in understanding could inform future microbiome-directed therapies that matter to people with IBD.

People with IBD often need biologic therapy during their reproductive years. This review compiles comparative evidence about pregnancy risks with different biologics to inform decisions about continuing or switching...

A potential link between ultra-processed food intake and Crohn’s relapse could influence dietary conversations for people in remission, but the current evidence is weak and not definitive.

FUT2-dependent intestinal fucosylation helps shape which gut microbes thrive and how the mucosa resists pathogens. For people with IBD, differences in FUT2 function and altered fucosylation may contribute to microbiome...

If blood bile acid patterns are reproducibly different in IBD and track with disease activity, they could become noninvasive biomarkers to help diagnose IBD or monitor flares. That would be useful for patients and...

Knowing which symptoms and non-invasive biomarkers most strongly associate with UC can help patients and clinicians decide who should be prioritized for diagnostic endoscopy and for monitoring disease activity.

Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.

CAR-Treg and Treg-cell therapies aim to specifically suppress harmful gut inflammation and could offer a new treatment option for people whose IBD does not respond to current drugs. Right now this is early-stage work —...

Protease and serpin activity affect the gut barrier, immunity, and microbial ecology—processes central to IBD. Integrating these pathways could help identify biomarkers or targets that explain why IBD varies between...

Microbial tryptophan metabolites may help restore the intestinal barrier via AhR signaling, a process that could reduce inflammation and symptom-driving permeability in IBD. Understanding this pathway could point to...

Clear, reproducible ultrasound definitions for transmural healing and response could help clinicians track deeper intestinal healing beyond mucosal assessment and allow trials to use consistent imaging endpoints.

If you have IBD, emerging forms of regulated cell death may help explain ongoing intestinal inflammation and could become targets for future tests or treatments. This review highlights multiple RCD pathways linked to...

Treatment resistance is a major hurdle in IBD care; this review maps how microbiota, immune imbalance, and epigenetics may work together to cause drug-resistant disease and suggests potential precision strategies that...

This narrative review surveys novel biomarkers and therapeutic strategies for adult IBD, topics that could affect diagnosis, monitoring, and future treatment options for people with Crohn's disease or ulcerative colitis.

Microbiome-based treatments target inflammation and microbial balance — central issues in IBD — and could offer new therapeutic options. This review collates clinical and mechanistic evidence but warns that results are...

If you or someone you care for is not responding to anti‑TNF drugs for ulcerative colitis, this review explains biological reasons why that may happen and points toward research directions that could lead to better tests...

Researchers are investigating circRNAs as potential biomarkers and therapeutic targets in IBD because they may help explain disease mechanisms and lead to better diagnostics or treatments in the future.

This review directly compares surgery-first versus biologic-first strategies for localized ileocaecal Crohn's disease and suggests early resection can lower later treatment needs and leave some patients off medication,...

This review highlights probiotic and synbiotic approaches centered on L. plantarum that aim to rebalance gut microbiota and support the intestinal barrier—areas of direct interest to people with IBD seeking adjunctive,...

Digital health tools could offer more continuous monitoring and self-management support for people with IBD, potentially helping detect flares earlier and improve quality of life. This review collects existing evidence...

FABP2 is presented as a sensitive biomarker of intestinal mucosal injury and a possible contributor to IBD mechanisms; if validated, it could improve disease monitoring and suggest new therapeutic targets.